Beyond Weight Loss: Semaglutide Could Curb Alcohol Cravings According to USC Study
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Zealand Pharma targets 15-20% weight loss with petrelintide trials in 2025
Discover Zealand Pharma's Q4 2024 earning highlights, key obesity pipeline advancements, and future plans for petrelintide and dapiglutide.
STAT19h
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...
STAT7h
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Lilly's next obesity drug serves up dramatic weight loss -- and side effects - report
Lilly's retatrutide shows remarkable weight loss in trials but raises concerns with side effects possibly linked to the drug like nausea and kidney stones. Read more here.
Eli Lilly obesity drug trial participants losing ‘too much weight,’ STAT reports
In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.